Chai Shai Chaishai with me
Business

Peter Thiel’s venture capital fund gives $280 million to Elon Musk’s brain implant company, Neuralink.

Neuralink, a biotechnology business founded by Elon Musk, recently said that it successfully secured $280 million in a fundraising round. This announcement was made through X, a social media site owned by Musk, previously recognized as Twitter.

The Series D funding round was spearheaded by Founders Fund, a venture capital firm headquartered in San Francisco and founded by Peter Thiel, a prominent billionaire known for his involvement in PayPal’s inception and his contentious reputation.

Neuralink expressed profound enthusiasm for the forthcoming phase of their operations.

The firm specializing in brain chip technology aims to establish a neural interface through implantable devices, enabling the connection between the human brain and a computer system. This objective has been pursued by entrepreneur Elon Musk for a duration of five years. To date, the organization has exclusively conducted experiments on animals, and has seen criticism subsequent to the demise of a primate during a project trial in 2022, wherein attempts were made to engage the animal in playing Pong, a computer-based game.

The utilization of macaque monkeys in experimentation has been observed in the research conducted by Neuralink. The firm has been actively engaged in the development of implantable chips, which are equipped with Bluetooth technology and are surgically inserted into the brains of these monkeys. Neuralink asserts that these chips possess the capability to establish communication with computers through a compact receiver.

The announcement regarding funding follows several months after Musk’s declaration of the company’s progression towards conducting human trials. During a recruiting event held in December, the billionaire stated that Neuralink has completed a significant portion of its documentation submission to the US Food and Drug Administration. Consequently, the company anticipates commencing human testing within a time frame of six months.

According to a report published by Reuters in December, staff have alleged that the company is engaging in hasty market entry, leading to instances of negligent animal fatalities and prompting a federal probe.

Prior to the mass production and widespread availability of Neuralink’s brain implants, it is imperative that they undergo the necessary regulatory approval process. In 2021, the Food and Drug Administration (FDA) published a document outlining their preliminary perspectives on brain-computer interface (BCI) technologies, acknowledging the tremendous advancement of this sector.

In a recent tweet, Neuralink declared its intention to recruit new personnel, extending an invitation to individuals who are interested in participating in technical endeavors aimed at the restoration of vision and mobility.

Show More

Related Articles

Leave a Reply

Your email address will not be published. Required fields are marked *

Back to top button